USP10 and metabolic dysfunction-associated steatotic liver disease: It can be seen that targeting to increase the expression of USP10 stabilizes SIRT6, increases its activity, inhibits SREBP1 and SREBP2 activity, reduces lipid synthesis and accumulation, and thus prevents the progression of NAFLD.